Evidence map›Paper›PMID 41964394›Full record

ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2026

The association between APOE 𝜀4 carrierships and the detection of amyloid positivity using an Alzheimer's disease proteomic blood test in asymptomatic Down syndrome.

Lubnaa Badriyyah Abdullah, Fan Zhang, Melissa Petersen, James Hall, Benjamin L Handen, Mark Mapstone, Brad Christian, Elizabeth Head, Sigan Harley, Howard Andrews and 17 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors.

Lubnaa Badriyyah AbdullahDepartment of Family Medicine, UNT Health Fort Worth, Fort Worth, Texas, USA.ORCID 0000-0002-3664-1075
Fan ZhangDepartment of Family Medicine, UNT Health Fort Worth, Fort Worth, Texas, USA.
Melissa PetersenDepartment of Family Medicine, UNT Health Fort Worth, Fort Worth, Texas, USA.
James HallDepartment of Family Medicine, UNT Health Fort Worth, Fort Worth, Texas, USA.
Benjamin L HandenDepartment of Psychiatry, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Mark MapstoneDepartment of Neurology, University of California, Irvine, California, USA.
Brad ChristianDepartment of Pediatrics, University of California, Irvine, School of Medicine, Orange, California, USA.
Elizabeth HeadDepartment of Pediatrics, University of California, Irvine, School of Medicine, Orange, California, USA.
Sigan HarleyUniversity of Wisconsin Madison, Waisman Center, Madison, Wisconsin, USA.
Howard AndrewsDepartment of Neurology New York, Columbia University, Vagelos College of Physicians and Surgeons, Taub Institute for Research on Alzheimer's Disease and the Aging Brain, New York, New York, USA.
Joseph H LeeDepartment of Neurology New York, Columbia University, Vagelos College of Physicians and Surgeons, Taub Institute for Research on Alzheimer's Disease and the Aging Brain, New York, New York, USA.
Dana TudorascuDepartment of Pediatrics, University of California, Irvine, School of Medicine, Orange, California, USA.
Christy HomDepartment of Psychiatry and Human Behavior, University of California, Irvine (UCI) School of Medicine, Orange, California, USA.
Shahid ZamanDepartment of Psychiatry, School of Clinical Medicine, University of Cambridge, Cambridge, UK.
Adam M BrickmanDepartment of Psychiatry and Human Behavior, University of California, Irvine (UCI) School of Medicine, Orange, California, USA.
Diana RosasDepartments of Neurology and Radiology, Harvard Medical School, Massachusetts General Hospital, Charlestown, Massachusetts, USA.
Annie CohenDepartment of Pediatrics, University of California, Irvine, School of Medicine, Orange, California, USA.
Jordan P HarpKentucky Neuroscience Institute & Sanders-Brown Center on Aging, University of Kentucky College of Medicine, Lexington, Kentucky, USA.
Frederick SchmittDepartment of Pediatrics, University of California, Irvine, School of Medicine, Orange, California, USA.
Lauren PtomeyUniversity of Kansas Medical Center, Kansas City, Kansas, USA.
Jeffrey M BurnsDepartment of Radiology, Department of Bioengineering, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Ira T LottDepartment of Pediatrics, University of California, Irvine, School of Medicine, Orange, California, USA.
Florence LaiDepartment of Pathology, University of California, Irvine, Irvine, California, USA.
Charles LaymonDepartment of Radiology, Department of Bioengineering, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Carlos CruchagaDepartment of Psychiatry, Washington University in St. Louis, St. Louis, Missouri, USA.
Sid O'BryantDepartment of Psychiatry, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Beau M AncesDepartment of Pathology, University of California, Irvine, Irvine, California, USA.

Funding

The Health & Aging Brain Study - Health Disparities (HABS-HD)U19AG078109 · NIA · UNIVERSITY OF NORTH TEXAS HLTH SCI CTR · PI LEIGH A JOHNSON · 2022 to 2026
$181.1M
Project 3: Biomarkers for DS Clinical TrialsU19AG068054 · NIA · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI ANCES, BEAU M · 2020 to 2025
$103.7M
Biomarkers of Alzheimer's Disease in Adults with Down SyndromeU01AG051412 · NIA · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI LOTT, IRA T., SCHUPF, NICOLE · 2015 to 2019
$26.3M
NiAD Supplement WashU Start UpU01AG051406 · NIA · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI HANDEN, BENJAMIN L, LAYMON, CHARLES · 2015 to 2019
$21.3M
Eunice Kennedy Shriver National Institute of Child Health and Human DevelopmentInvestigation of Co-occurring conditions across the Lifespan to Understand Down syndrome (NIH INCLUDE Project)NIA NIH HHS U01 AG051406NIA NIH HHS U01 AG051412NIA NIH HHS U19 AG068054NIA NIH HHS U19 AG078109
6 · The paper itself

Abstract

introductionThis study evaluates plasma-based proteomic profiles for predicting amyloid positivity in adults with Down syndrome (DS) and examines the impact of apolipoprotein E ε4 (APOE ε4) on test performance.

methodsCross-sectional data from 290 adults with DS were analyzed using single molecule array (SIMOA) technology to measure plasma amyloid beta (Aβ)42, Aβ40, neurofilament light chain (NfL), glial fibrillary acidic protein (GFAP), tau phosphorylated at threonine 181, and total tau. Amyloid burden was quantified using Pittsburgh Compound B and (18)F-florbetapir Aβ positron emission tomography. Support vector machine analyses were conducted with biomarkers as predictors and age, sex, and APOE ε4 carrier status as covariates.

resultsAge, GFAP, and NfL contributed the most to the model performance. The proteomic profile achieved an area under the curve (AUC) of 96% in models with and without APOE ε4. DISCUSSION: These findings suggest that plasma proteomic biomarkers can effectively identify amyloid positivity in adults with DS and may support clinical triage, monitoring, and selection for clinical trials, independent of APOE ε4 status.

Indexed as

Alzheimer DiseaseAmyloid beta-PeptidesApolipoprotein E4Down SyndromeProteomicsAdultAniline CompoundsBiomarkersCarbolinesCross-Sectional StudiesEthylene GlycolsFemaleHeterozygoteHumansMaleMiddle AgedAmyloid beta-Peptidesamyloid beta-protein (1-40)amyloid beta-protein (1-42)Aniline CompoundsApolipoprotein E4BiomarkersCarbolinesEthylene Glycolsneurofilament protein LNeurofilament ProteinsPeptide Fragmentstau ProteinsAlzheimer's diseaseamyloid positron emission tomographyblood‐based biomarker testDown syndromeproteomicssupport vector machine learning

Identifiers

PMID41964394
PMCPMC13069467

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.